⚠ Evidence warning: Clinical trials or other evidence do not support the claims that tyrosine helps attention-deficit/hyperactivity disorder, apathetic depression and stimulant withdrawal. This page keeps it as a report of what people, websites or other media say.

Tyrosine for Dopamine & Mood

Pigmented dopamine nerve cells in the midbrain
Pigmented dopamine nerve cells in the midbrain
The substantia nigra, the dark band of dopamine cells
The substantia nigra, the dark band of dopamine cells

Tyrosine is the chemical raw material of the entire catecholamine cascade: dopamine, norepinephrine, and epinephrine all begin as a single hydroxylation of tyrosine to L-DOPA, catalyzed by the rate-limiting enzyme tyrosine hydroxylase. Three nuclei in the human brain — the substantia nigra (motor dopamine), the ventral tegmental area (motivational dopamine), and the locus coeruleus (norepinephrine arousal) — depend on adequate tyrosine substrate to maintain their signaling. This is the substrate-pharmacology foundation for tyrosine's tested roles in attention-deficit/hyperactivity disorder (ADHD), depression, mood under stress, withdrawal management, and Parkinson's disease. The evidence is strongest for acute stress applications and mixed for chronic depression, with a clinical pattern that maps tightly to the underlying mechanism — tyrosine helps where catecholamine substrate is genuinely depleted, and helps little where the deficit is downstream of the substrate pool.


🎯 Interactive Visualization Dopamine, Reward & How Habits Hijack You Dopamine is not the pleasure chemical. Watch the spike migrate from the reward to the cue — then withhold the reward and see it dip below zero. That dip is craving. Launch →

Table of Contents

  1. Tyrosine Hydroxylase — The Rate-Limiting Enzyme
  2. The Full Catecholamine Cascade (Tyrosine → DOPA → DA → NE → EPI)
  3. The Three Brain Dopamine Systems
  4. BH4 Cofactor — The Other Half of the Reaction
  5. Tyrosine for Depression — The Mixed Evidence
  6. Early Amino-Acid Trials in Attention-Deficit/Hyperactivity Disorder, 1985 and 1987
  7. Comparison to Methylphenidate and Amphetamine
  8. Parkinson's Disease and the L-DOPA Comparison
  9. Withdrawal Management (Stimulants, Caffeine, Cocaine)
  10. The Cofactor Stack — B6, Iron, Folate, BH4, S-Adenosylmethionine
  11. How Tyrosine Behaves in Older Adults
  12. Key Research Papers
  13. Connections
  14. Featured Videos

Tyrosine Hydroxylase — The Rate-Limiting Enzyme

Tyrosine hydroxylase (TH; EC 1.14.16.2) is the enzyme that hydroxylates the aromatic ring of L-tyrosine to produce L-DOPA (L-3,4-dihydroxyphenylalanine). It uses molecular oxygen as oxidant and tetrahydrobiopterin (BH4) as the obligate redox cofactor, with iron in the active site. The reaction is:

L-Tyrosine + O2 + BH4 → L-DOPA + H2O + BH2 (quinonoid)

TH is the rate-limiting enzyme of the entire catecholamine pathway because the subsequent steps (DOPA → dopamine, dopamine → norepinephrine, norepinephrine → epinephrine) all proceed faster than TH can supply L-DOPA, and have larger and more easily replenished pools. Whenever a tissue or neuron needs more catecholamines, the controlling variable is TH activity.

TH activity is regulated at multiple levels:

The therapeutic relevance: anything that can elevate TH activity (substrate, cofactors, phosphorylation), reduce feedback inhibition (lower the catecholamine pool), or accelerate the downstream cascade will increase catecholamine output. Tyrosine supplementation operates at the substrate-availability node; this matters specifically when TH has been pushed into the substrate-limited regime by acute physiological demand.

The main source for the idea that brain catecholamine production responds to tyrosine supply is the 2007 review by Fernstrom and Fernstrom. In everyday words, it says that how fast the brain makes these signal chemicals depends on how much tyrosine reaches it, and that eating more protein raises brain tyrosine. The extra output appears only in nerve cells that are actively firing, so the boost shows up where there is demand. The review also states that what the body normally uses this link for is unknown.

Back to Table of Contents

The Full Catecholamine Cascade (Tyrosine → DOPA → DA → NE → EPI)

The catecholamine synthesis pathway is one of the most elegantly modular biochemical cascades in human physiology. Five reactions, five enzymes, three end products, all from a single starting amino acid:

  1. Phenylalanine → Tyrosine (phenylalanine hydroxylase, PAH, liver) — this is the reaction defective in phenylketonuria; it is also why dietary phenylalanine intake matters for catecholamine synthesis even when no tyrosine is directly consumed
  2. Tyrosine → L-DOPA (tyrosine hydroxylase, TH, the rate-limiting step in catecholaminergic neurons)
  3. L-DOPA → Dopamine (aromatic L-amino acid decarboxylase, AADC, fast, ubiquitous, requires pyridoxal-5-phosphate / Vitamin B6)
  4. Dopamine → Norepinephrine (dopamine beta-hydroxylase, DBH, requires copper and ascorbate, occurs inside synaptic vesicles of noradrenergic neurons)
  5. Norepinephrine → Epinephrine (phenylethanolamine N-methyltransferase, PNMT, occurs in adrenal medullary chromaffin cells and a few brainstem nuclei, requires S-adenosylmethionine as methyl donor)

Each cell type expresses a different subset of the cascade. Dopaminergic neurons (substantia nigra, ventral tegmental area) express TH and AADC but not DBH or PNMT — they stop at dopamine. Noradrenergic neurons (locus coeruleus, lateral tegmental area) express TH, AADC, and DBH but not PNMT — they stop at norepinephrine. Adrenal medullary chromaffin cells express all five (PAH is in the liver but PAH is also expressed in many other tissues at low levels), allowing the full cascade through to epinephrine.

Tyrosine supplementation therefore raises the substrate pool for whichever step a given cell type is performing. In a dopaminergic neuron, the effect is increased dopamine output. In a noradrenergic neuron, increased norepinephrine. In the adrenal medulla, increased epinephrine. The same molecule supports all three outputs because TH sits at the common starting point.

Note the cofactor requirements: B6 (PLP) for AADC, copper and ascorbate (Vitamin C) for DBH, SAMe for PNMT, BH4 and iron for TH (and for PAH). These are the cofactors that constrain the cascade when present at suboptimal levels. The discussion of tyrosine for mood always becomes inseparable from the discussion of B6, iron, copper, ascorbate, and S-adenosylmethionine (SAMe).

Back to Table of Contents

The Three Brain Dopamine Systems

Brain dopamine is not one system — it is three anatomically and functionally distinct pathways, each originating from a different cluster of dopaminergic cell bodies and projecting to different targets:

  1. Nigrostriatal pathway (substantia nigra pars compacta → dorsal striatum) — the motor system. Degeneration here produces Parkinson's disease, the prototypical dopamine-deficiency syndrome. The clinical motor signs (bradykinesia, rigidity, resting tremor, postural instability) emerge when nigrostriatal dopamine cell loss exceeds approximately 70%.
  2. Mesolimbic / mesocortical pathway (ventral tegmental area → nucleus accumbens, prefrontal cortex) — the motivation, reward, and executive-function system. Implicated in addiction (excess phasic ventral tegmental area firing in response to drug cues), depression (reduced tonic mesolimbic dopamine), schizophrenia (deranged mesolimbic / mesocortical balance), attention-deficit/hyperactivity disorder (reduced prefrontal dopamine tone), and the pleasure-anticipation response to food, sex, music, and achievement.
  3. Tuberoinfundibular pathway (arcuate nucleus of hypothalamus → median eminence) — the prolactin-suppression system. Tonic dopamine release into the pituitary portal circulation tonically suppresses prolactin secretion. Antipsychotic drugs that block D2 receptors release this tonic suppression and cause hyperprolactinemia.

Tyrosine supplementation affects all three systems insofar as TH substrate availability is rate-limiting in each. The clinical implications differ:

Back to Table of Contents

BH4 Cofactor — The Other Half of the Reaction

TH cannot hydroxylate tyrosine without tetrahydrobiopterin (BH4), and this cofactor pathway is the underappreciated half of the catecholamine-substrate story. BH4 is synthesized de novo from GTP in three enzymatic steps (GTP cyclohydrolase 1 → 6-pyruvoyl tetrahydropterin synthase → sepiapterin reductase) and is recycled after each hydroxylation reaction by quinonoid dihydropteridine reductase and pterin-4a-carbinolamine dehydratase.

The BH4 recycling and salvage reductases (dihydropteridine reductase and dihydrofolate reductase) use reduced nicotinamide adenine dinucleotide (NADH)/reduced nicotinamide adenine dinucleotide phosphate (NADPH) as reducing power, which links catecholamine synthesis to overall mitochondrial redox state. Oxidative stress, mitochondrial dysfunction, and high inflammatory load can drain the reduced nicotinamide adenine dinucleotide pool and indirectly impair BH4 recycling, blunting catecholamine synthesis even with adequate tyrosine and adequate TH expression. This is one molecular substrate behind the "fatigue plus low mood" pattern in chronic inflammatory conditions, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and long post-viral states.

BH4 production is also tied to other nutrients. Human GTP cyclohydrolase I holds an essential zinc ion in its active site (Auerbach 2000), and the 2011 Werner review links folate metabolism to BH4 through the dihydrofolate reductase salvage route. Iron sits in tyrosine hydroxylase itself. On this model, functional folate deficiency or iron deficiency can blunt the catecholamine cascade. Several supplements address the BH4 pathway directly:

On this model, tyrosine substrate loading without enough BH4 cofactor may underperform expectations, and in people with functional folate or B12 issues, iron deficiency, or chronic inflammatory states, tyrosine alone may not change the catecholamine problem.

Back to Table of Contents

Tyrosine for Depression — The Mixed Evidence

The intuitive hypothesis — if dopamine and norepinephrine deficiency contribute to depression, and tyrosine is the precursor of both, then tyrosine supplementation should help depression — was tested aggressively in the 1980s and 1990s and has been re-tested intermittently since. The results have been distinctly mixed.

Positive small trials. A handful of early studies suggested tyrosine could augment standard antidepressants or even produce stand-alone benefit in atypical depression, dysthymia, or depressive episodes with prominent fatigue and apathy. Doses ranged from 2 to 12 g/day, typically for 4–8 weeks. Effect sizes when present were modest.

A larger negative trial. The pivotal Gelenberg et al. 1990 double-blind trial enrolled 65 outpatients with major depression and randomized them to 100 mg/kg/day tyrosine (about 7 g), imipramine 2.5 mg/kg/day or placebo. After 4 weeks there was no evidence that tyrosine had antidepressant activity. The abstract does not state how imipramine compared with placebo on mood; it reports lower excretion of a norepinephrine breakdown product (MHPG) and more dry mouth with imipramine. The trial was widely interpreted as definitive negative evidence against tyrosine monotherapy for typical major depression.

The reconciliation. Most depression is not acute catecholamine substrate depletion. Most depression involves slow, chronic dysregulation of monoamine signaling at the receptor level, downstream of synthesis — receptor desensitization, glutamate-system involvement, neurogenic effects, neuroinflammation, hypothalamic-pituitary-adrenal-axis dysregulation, circadian disruption. Loading the substrate pool does not address any of these. This is why selective serotonin reuptake inhibitors (which act at the reuptake transporter) and serotonin-norepinephrine reuptake inhibitors (which act at both reuptake transporters) outperform tyrosine substantially in conventional major depressive disorder.

A 2015 review of tyrosine studies by Jongkees and colleagues concluded that its potential for treating clinical disorders "seems limited" and that its potential for enhancing physical exercise "seems minimal". The same review found that tyrosine does seem to help thinking in short stressful or demanding situations, when nerve signalling is otherwise intact and dopamine or norepinephrine is temporarily depleted.

The subgroup practitioners point to. People with depression characterized predominantly by:

are the people in whom practitioners describe trying tyrosine. The regimen they describe is 2–3 g/day in divided doses for 4–6 weeks, alongside other treatment, stopping if there is no response within 4 weeks. These are practice reports, not trial results.

Tyrosine has not been shown to replace treatment of major depression; the double-blind trial above found no antidepressant activity. The mood section of this page reports research and practice as context. See our Depression page for a fuller treatment.

Back to Table of Contents

Early Amino-Acid Trials in Attention-Deficit/Hyperactivity Disorder, 1985 and 1987

The early trials came from one research group. Wood and colleagues in 1985 tested DL-phenylalanine, not tyrosine: a 2-week double-blind crossover against placebo in 19 adults with attention deficit disorder, residual type (the diagnostic label of the era), of whom 13 finished. Global improvement only "approached significance", while mood and mood swings improved significantly. Those who responded and stayed on the drug openly lost all the benefit within 3 months, and a later open trial of L-phenylalanine produced no clinical effect.

The 1987 follow-up by the same group (Reimherr and colleagues) was the tyrosine trial: an open 8-week trial of L-tyrosine in 12 adults. Eight showed a marked to moderate response in 2 weeks; at 6 weeks those eight had developed tolerance, and the authors concluded that L-tyrosine "is not useful" in this condition. The abstract gives no dose; this page has carried 50–200 mg/kg/day for it. One proposed explanation for the tolerance, not stated in the abstract, is TH down-regulation in response to the elevated substrate.

This was an open trial, not a placebo-controlled one. A Europe PMC search for this review found no placebo-controlled trial of tyrosine supplements in this condition.

The honest interpretation. Tyrosine is not a replacement for methylphenidate or amphetamine in moderate-to-severe attention-deficit/hyperactivity disorder — the prescription stimulants produce substantially larger effect sizes through directly increasing extracellular dopamine and norepinephrine via reuptake blockade (methylphenidate) or release promotion (amphetamine), rather than supplying substrate. The tolerance seen in the 1987 trial also limits sustained benefit.

Complementary uses that practitioners and people report:

Doses described in practice for attention-deficit/hyperactivity disorder adjunct use are 500–1500 mg twice daily, taken on a relatively empty stomach 30–60 minutes before stimulant dosing or before high-demand cognitive periods; no trial located tested them. See attention-deficit/hyperactivity disorder page for full treatment context.

Back to Table of Contents

Comparison to Methylphenidate and Amphetamine

To set realistic expectations: tyrosine and stimulant medications are fundamentally different mechanistically and produce fundamentally different effect sizes. Comparison:

A 2018 network meta-analysis of 133 double-blind trials gives one measured set of the stimulant figures. On clinicians' ratings against placebo, the standardised difference was 1.02 for amphetamines and 0.78 for methylphenidate in children and adolescents, and 0.79 and 0.49 in adults. The difference from tyrosine is explained by mechanism: substrate loading helps modestly when substrate is limiting; reuptake blockade and release promotion produce large effects regardless of synthesis state because they directly elevate the signaling pool.

Tyrosine has not displaced prescription stimulants for moderate-to-severe attention-deficit/hyperactivity disorder. Practitioners describe a complementary role — supporting the substrate pool that the accelerated stimulant-driven catecholamine turnover is drawing from — and there is some theoretical support for tyrosine reducing the late-day crash some stimulant users experience, although controlled trials in this specific use are scarce.

Back to Table of Contents

Parkinson's Disease and the L-DOPA Comparison

Parkinson's disease is the prototypical dopamine-deficiency disorder. Selective degeneration of dopaminergic neurons in the substantia nigra pars compacta produces a progressive striatal dopamine deficiency that manifests clinically when cell loss exceeds approximately 70%. Direct precursor replacement with L-DOPA (typically combined with carbidopa to block peripheral conversion) is the cornerstone of treatment and remains the most effective symptomatic therapy in Parkinson's disease.

Could tyrosine substitute for L-DOPA in Parkinson's? In principle, more tyrosine should produce more L-DOPA via residual TH activity. In practice, tyrosine has not replaced L-DOPA in Parkinson's disease, and these are the reasons usually given:

  1. The bottleneck in advanced Parkinson's disease is TH-expressing cell number, not substrate. By the time symptoms emerge, 70% of TH-expressing neurons are gone. Adding substrate to a depleted enzyme pool produces marginal increase in L-DOPA output. Adding L-DOPA directly bypasses the missing enzyme entirely.
  2. Tyrosine and L-DOPA compete at LAT1 for blood-brain barrier transport. High-dose tyrosine in a Parkinson's patient on L-DOPA therapy can actually reduce L-DOPA delivery to brain, worsening rather than helping symptoms. This is a hard clinical pitfall — well-intentioned use of tyrosine in a person with Parkinson's disease on carbidopa-levodopa can produce a Parkinsonian deterioration.
  3. L-DOPA itself has shorter half-life and more predictable kinetics than the tyrosine → L-DOPA conversion, making titration and dose-effect prediction substantially easier with direct precursor.

A small 1989 French report points the other way. Lemoine and colleagues gave long-term L-tyrosine to ten people with Parkinson's disease, five new to treatment and five already on L-DOPA or dopamine agonists. For some, 3 years on tyrosine was followed by better clinical results and many fewer side effects than with those drugs. The abstract describes no control group, and the authors called for further study.

What this means for people on levodopa: tyrosine and L-DOPA compete for the same transport into the brain, which the research raises as a concern for people taking carbidopa-levodopa with high-dose tyrosine. The possible exception described is the very early Parkinson's disease phase before symptoms emerge, where substrate support might theoretically slow symptomatic conversion — but this has not been demonstrated in controlled trials.

Back to Table of Contents

Withdrawal Management (Stimulants, Caffeine, Cocaine)

Chronic stimulant use depletes the catecholamine substrate pool by accelerating turnover over weeks to months. Abrupt discontinuation produces the well-known withdrawal pattern: profound fatigue, low mood, anhedonia, hypersomnia, intense drug craving, attentional impairment — the so-called "crash" that follows cocaine or amphetamine binges, and the milder version that follows abrupt discontinuation of caffeine, prescription stimulants, or nicotine.

The catecholamine-depletion model of stimulant withdrawal suggests substrate replenishment with tyrosine should accelerate recovery. Reports from practice and a few small studies bear on this hypothesis:

The summary: tyrosine for withdrawal management is mechanistically plausible, and practitioners regard it as an adjunct, unlikely to do harm at moderate doses (1–3 g/day) for short periods (2–6 weeks). The small studies located did not find a significant benefit, and it has not been shown to replace addiction treatment.

Back to Table of Contents

The Cofactor Stack — B6, Iron, Folate, BH4, S-Adenosylmethionine

Practitioners describe tyrosine alone as rarely enough, because the catecholamine cascade requires multiple cofactors and any of them can be the rate-limiting node. The "tyrosine stack" they describe for the full pathway:

Practitioners describe this cofactor stack for people with a suspected catecholamine substrate problem (apathetic depression, post-stimulant withdrawal, postpartum, chronic stress, documented iron or B-vitamin deficiency), not for everyone. No trial of the full combination was located. The list illustrates the principle that "tyrosine deficiency" is rarely the whole story.

Back to Table of Contents

How Tyrosine Behaves in Older Adults

In a double-blind randomised crossover trial, 17 older adults aged 60–75 each took single doses of 100, 150 and 200 mg per kg of body weight; 17 young adults aged 18–35 took 150 mg/kg for comparison. Blood tyrosine rose more in the older adults than in the young adults on the same dose. Working memory on a demanding test got worse as the dose went up, especially in the older adults whose blood levels rose most. In this trial higher doses did not bring better working memory in later life. It tested single doses, so long-term use was not measured.

Back to Table of Contents

Key Research Papers

  1. Fernstrom JD, Fernstrom MH (2007). Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. Journal of Nutrition. — PubMed PMID: 17513421
  2. Gelenberg AJ et al. (1990). Tyrosine for depression: a double-blind trial. Journal of Affective Disorders. — PubMed PMID: 2142699
  3. Wood DR et al. (1985). Treatment of attention deficit disorder with DL-phenylalanine. Psychiatry Research. — PubMed PMID: 3903813
  4. Wood DR, Reimherr FW, Wender PH (1985). Amino acid precursors for the treatment of attention deficit disorder, residual type. Psychopharmacology Bulletin. — PubMed PMID: 3885291
  5. Reimherr FW et al. (1987). An open trial of L-tyrosine in the treatment of attention deficit disorder, residual type. American Journal of Psychiatry. — PubMed PMID: 3300376
  6. Nagatsu T et al. (1964). Tyrosine hydroxylase: the initial step in norepinephrine biosynthesis. Journal of Biological Chemistry. — PubMed PMID: 14216443
  7. Daubner SC et al. (2011). Tyrosine hydroxylase and regulation of dopamine synthesis. Archives of Biochemistry and Biophysics. — PubMed PMID: 21176768
  8. Werner ER et al. (2011). Tetrahydrobiopterin: biochemistry and pathophysiology. Biochemical Journal. — PubMed PMID: 21867484
  9. Beard JL (2003). Iron deficiency alters brain development and functioning. Journal of Nutrition. — PubMed PMID: 12730445
  10. Hoehn MM, Yahr MD (1967). Parkinsonism: onset, progression and mortality. Neurology. — PubMed PMID: 6067254
  11. Volkow ND et al. (2009). Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. — PubMed PMID: 19738093
  12. Lemoine P, Robelin N, Sebert P, Mouret J (1989). [L-tyrosine: a long term treatment of Parkinson's disease]. C R Acad Sci III. — PubMed PMID: 2502304
  13. Goldstein DS, Eisenhofer G, Kopin IJ (2003). Sources and significance of plasma levels of catechols and their metabolites in humans. Journal of Pharmacology and Experimental Therapeutics. — PubMed PMID: 12649306
  14. van Spronsen FJ et al. (2021). Phenylketonuria. Nature Reviews Disease Primers. — PubMed PMID: 34017006
  15. Auerbach G et al. (2000). Zinc plays a key role in human and bacterial GTP cyclohydrolase I. Proceedings of the National Academy of Sciences of the USA. — PubMed PMID: 11087827
  16. Jongkees BJ, Hommel B, Kühn S, Colzato LS (2015). Effect of tyrosine supplementation on clinical and healthy populations under stress or cognitive demands: a review. Journal of Psychiatric Research. — PubMed PMID: 26424423
  17. van de Rest O, Bloemendaal M, de Heus R, Aarts E (2017). Dose-dependent effects of oral tyrosine administration on plasma tyrosine levels and cognition in aging. Nutrients. — PubMed PMID: 29168741
  18. Chadwick MJ, Gregory DL, Wendling G (1990). A double-blind amino acids, L-tryptophan and L-tyrosine, and placebo study with cocaine-dependent subjects in an inpatient chemical dependency treatment center. American Journal of Drug and Alcohol Abuse. — PubMed PMID: 2288326
  19. Galloway GP et al. (1996). A historically controlled trial of tyrosine for cocaine dependence. Journal of Psychoactive Drugs. — PubMed PMID: 8895116
  20. Cortese S et al. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. — PubMed PMID: 30097390

PubMed Topic Searches

  1. PubMed: Tyrosine and dopamine synthesis
  2. PubMed: Tyrosine and depression
  3. PubMed: Tyrosine and ADHD
  4. PubMed: Tyrosine hydroxylase regulation
  5. PubMed: Tyrosine and cocaine withdrawal

Back to Table of Contents

Connections

Back to Table of Contents